CYTH Stock Analysis
CY
Uncovered
Cyclo Therapeutics Inc is uncovered by Eyestock quantitative analysis.
Rating
To assess the quality of a company's business, we have collected all financial data from the statements and presented them in the form of a single number - the company's rating. Rating value of 100 is the threshold for determining a viable investment.
Low score
Market cap $B
0.019
Dividend yield
—
Shares outstanding
10.555 B
Cyclo Therapeutics, Inc. engages in the development of cyclodextrin-based biopharmaceuticals for the treatment of disease. The company is headquartered in Gainesville Florida, Florida and currently employs 9 full-time employees. The company went IPO on 2004-02-27. The Company’s lead drug candidate, Trappsol Cyclo (hydroxypropyl beta cyclodextrin) is a treatment for Niemann-Pick Type C disease (NPC). NPC is a rare and fatal cholesterol metabolism disease that impacts the brain, lungs, liver, spleen, and other organs. The company is also focusing on the use of cyclodextrins in the treatment of Alzheimer's disease. Its product lines include Trappsol and Aquaplex. The firm also sells cyclodextrins and related products to the pharmaceutical, nutritional, and other industries, primarily for use in diagnostics and specialty drugs. The firm sells its chemical products directly to customers in the pharmaceutical, diagnostics, and industrial chemical industries, and to chemical supply distributors.